Humanigen to Present at Multiple Investor Conferences in March
February 25 2021 - 7:30AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical
stage biopharmaceutical company focused on preventing and treating
an immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab™, today announced that the Company’s
management team will present and host meetings with investors at
the H.C. Wainwright Global Life Sciences Conference being held from
March 9-10, 2021, the Roth Conference being held from March 15-17,
2021, and the Oppenheimer Annual Healthcare Conference being held
from March 16-17, 2021.
Management will discuss its Phase 3 clinical trial of lenzilumab
in patients hospitalized with COVID-19 including the timeline for
the topline data release and the submission for Emergency Use
Authorization (EUA) to the U.S. Food and Drug Administration,
provide an update on the commercial preparation ahead of a
potential EUA for lenzilumab and an overview of the Company’s other
development programs.
Details for the upcoming conferences are below:
Roth Conference
Presentation viewable starting on Friday,
March 5, 2021 Webcast Link:
https://wsw.com/webcast/roth35/hgen/1811466
H.C. Wainwright Global Life Sciences Conference
Presentation viewable starting on Tuesday,
March 9, 2021 at 7:00 AM ET Webcast Link:
https://journey.ct.events/view/75ac9aa6-fe6f-4694-bdb5-f04518258a98
Oppenheimer Annual Healthcare Conference
Presentation Date: Wednesday, March 17, 2021
Presentation Time: 3:50 PM ET Webcast Link:
https://wsw.com/webcast/oppenheimer9/hgen/2693482
About Humanigen, Inc.
Humanigen, Inc. is developing
its portfolio of clinical and pre-clinical therapies for the
treatment of cancers and infectious diseases via its novel,
cutting-edge GM-CSF neutralization and gene-knockout platforms.
Humanigen believes that its GM-CSF neutralization and gene-editing
platform technologies have the potential to reduce the inflammatory
cascade associated with coronavirus infection. Humanigen’s
immediate focus is to prevent or minimize the cytokine release
syndrome that precedes severe lung dysfunction and ARDS in serious
cases of SARS-CoV-2 infection. Humanigen is also focused on
creating next-generation combinatory gene-edited CAR-T therapies
using strategies to improve efficacy while employing GM-CSF gene
knockout technologies to control toxicity. In addition, Humanigen
is developing its own portfolio of proprietary first-in-class
EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various
eosinophilic disorders. Humanigen is also exploring the
effectiveness of its GM-CSF neutralization technologies (either
through the use of lenzilumab as a monoclonal antibody or through
GM-CSF gene knockout) in combination with other CAR-T, bispecific
or natural killer (NK) T cell engaging immunotherapy treatments to
break the efficacy/toxicity linkage, including to prevent and/or
treat graft-versus-host disease (GvHD) in patients undergoing
allogeneic hematopoietic stem cell transplantation (HSCT).
Additionally, Humanigen and Kite, a Gilead Company, are evaluating
lenzilumab in combination with Yescarta® (axicabtagene ciloleucel)
in patients with relapsed or refractory large B-cell lymphoma in a
clinical collaboration. For more information, visit
www.humanigen.com and follow Humanigen on LinkedIn, Twitter and
Facebook.
Forward-Looking Statements
This release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
"will," "expect," "intend," "plan," "potential," "possible,"
"goals," "accelerate," "continue," and similar expressions identify
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties including, but not limited
to, the risks inherent in our lack of profitability and need for
additional capital to grow our business; our dependence on partners
to further the development of our product candidates; the
uncertainties inherent in the development, attainment of the
requisite regulatory approvals and launch of any new pharmaceutical
product; the outcome of pending or future litigation; and the
various risks and uncertainties described in the "Risk Factors"
sections and elsewhere in the Company's periodic and other filings
with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005165/en/
Humanigen Media Grace Catlett RXMD gcatlett@rxmedyn.com
516-318-8563
Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024